As a result, ofatumumab has a greater potential to induce B cell apoptosis independently of p53 than rituximab, and has been shown to be efficacious and non-toxic in relapsed B-CLL refractory to fludarabine and alemtuzumab; a group that commonly possess TP53 mutations and/or deletions [18]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.